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Most individuals who receive warfarin therapy are elderly patients with atrial fibrillation and 
acute or recurrent venous thromboembolism. Anticoagulation in elderly people poses unique 
challenges because they are simultaneously at higher risk for recurrent thromboembolism and 
major bleeding, including catastrophic intracranial haemorrhage. The effectiveness of 
warfarin therapy is strongly linked to the proportion of time that patients spend in the target 
INR range (TTR).1, 2 The risk of death, myocardial infarction, major bleeding and stroke or 
systemic embolism are all related to INR control.3  
In Australia, the Department of Veterans’ Affairs (DVA) introduced a system of 
providing formal medication reviews for Australian veterans in 1999, which was followed by 
the HMR program (available to all members of the Australian public) in 2001. For veterans 
taking warfarin, these reviews provide an opportunity for patient education and review of 
warfarin management in the community setting. General practitioners refer patients to an 
accredited pharmacist who undertakes a home visit, identifying any medication-related 
problems, including potential underuse, overuse, adverse effects, compliance and knowledge 
problems, or hoarding. The pharmacist provides a report to the doctor who has responsibility 
for follow-up with the patient. The potential benefits of patients receiving a pharmacist-
conducted medication review were established in several large research projects performed in 
the late 1990s.4, 5 These studies found that HMRs resulted in the resolution of medication-
related problems and showed trends in reduced medication costs.  
A study by Roughead et al. assessed the effect of HMRs in Australian veterans and 
war widows taking warfarin retrospectively using administrative claims data.6 The study 
identified a 79% reduction in the likelihood of hospitalisation for bleeding between two and 
six months following the HMR (hazard ratio 0.21, 95% CI 0.05 - 0.87). This beneficial effort 
was not evident 6 to 12 months following review. As INR testing and TTR were not assessed 
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in the study, it is unclear whether improved INR control occurred as a result of the HMR, or 
whether the benefits occurred independently of improved INR control.  
We aimed to determine whether HMRs are associated with improved INR control, and 
observe the degree of INR control in this population. 
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Materials and Methods 
The DVA database 
The Australian DVA claims databases contain details of all prescription medicines, medical 
and allied health services and hospitalisations provided for which DVA pay a subsidy. At the 
time of the study, the data file contained 140 million pharmacy records, 200 million medical 
and allied health service records and over 6 million hospital records for a treatment population 
of 310,000 veterans. The DVA maintain a client file, which includes data on gender, date of 
birth, date of death and family status. Medicines are coded in the dataset according to the 
World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification7 
and the Schedule of Pharmaceutical Benefits item codes.8 Hospitalisations are coded 
according to the WHO International Classification of Diseases (ICD) classification.9  
 
Study design and data collection 
A retrospective cohort study was undertaken to compare the degree of INR control in veterans 
taking warfarin who were exposed and not exposed to HMRs. Eligible veterans were initially 
identified and selected by the DVA based on data from their patient database. To be eligible 
for inclusion into this study, veterans were screened by the DVA to meet the following 
inclusion criteria: possess a Gold repatriation benefit card (eligibility for full entitlements), 
dispensed warfarin during the study period (1st January 2007 to 31st December 2009), and 
residing at home (as opposed to a residential aged-care facility).  
The DVA identified a list of veterans who met the inclusion criteria and who had also 
had an HMR prior to 30th June 2009. This allowed for data to be available for at least 6 
months of data following the HMR in the group exposed to HMRs. The DVA then randomly 
selected a matching number of veterans who met the inclusion criteria who had not been 
exposed to an HMR in the study period. The identified veterans were sent an information 
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sheet and consent form. A list of veterans who consented to be involved in the study was 
generated and sent to the DVA for data extraction. 
Data provided by the DVA included age, sex, remoteness,10 number of co-morbidities, 
dispensed medications, dates of HMR claims, and health services utilisation (hospitalisations 
(including diagnoses and procedures), general practitioner visits and specialist visits). The 
research team then contacted pathology laboratories that had claimed payment from DVA for 
measuring the veteran’s INR.  
 
Formation of HMR and control groups 
The ‘HMR’ group were those who met the eligibility criteria, had received an HMR, and had 
at least two dispensings of warfarin in the six months prior to the HMR. The ‘control’ group 
was comprised of veterans who met the eligibility criteria and who had an average at least two 
dispensings of warfarin per six months between the first and final dispensing during the study 
period (to identify regular warfarin use), had at least three months between their first and final 
dispensing of warfarin (to identify long-term warfarin use) and had a first warfarin dispensing 
date before 1st January 2009 (to allow adequate time for a minimum of six months follow-up 
within the study period). 
Eligible veterans in the control group were randomly allocated to an index month in 
the study period to match the time of the HMR in the HMR group. Control group veterans 
were only matched once in the study period.  
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Data handling and statistics 
Data were analysed using SPSS 19.0 for Windows (IBM Corporation, New York, United 
States). Demographic variables were compared between the HMR and control groups using 
the following methods: paired and unpaired t-tests were used for normally distributed 
continuous variables; the non-parametric Mann-Whitney test was used for non-normal data. 
Categorical variables were analysed using the chi-square test. Fisher's exact test was used 
when at least one of the variables had fewer than five patients or events. Statistical 
significance was set at p < 0.05.  
The primary outcome was the percentage TTR, calculated using Rosendaal’s linear 
interpolation method,11 for the six months prior to the HMR or index date, compared to the 
six months following the HMR or index date. An INR target range of 2.0 to 3.0 was assumed 
for this analysis as specific diagnoses for the condition requiring anticoagulation were not 
available for the majority of patients and a range of 2.0 to 3.0 was considered to be 
appropriate for most elderly patients. The literature suggests that patients in the community 
spend 50-60% of their time within the target range. At a power of 80% and statistical 
significance set at 0.05, a minimum of 75 patients analysed before and after HMR was 
required to detect a 10% difference in the percentage TTR. 
The composite incidence of major bleeding and major thrombotic events resulting in 
hospitalisation occurring within six months of the HMR or index date was a secondary 
outcome. The ICD codes used to determine the primary diagnosis of hospitalisation 
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Results 
Figure 1 shows a flow diagram of recruitment of veterans into the study. The DVA selected 
3,884 veterans according to the project methodology, from which the research team received 
1,213 replies (31.2% response rate). A total of 1,029 veterans who replied provided their 
consent and were eligible for inclusion in the project. There were a total of 818 veterans who 
were allocated to the HMR (n = 281) or control groups (n = 537). INR data was available for 
a total of 344 of 818 (42.1%) veterans. At least two INR results were required to allow 
calculation of the TTR; veterans with only one INR result in the specified timeframe were 
excluded from the respective analyses. A total of 321 veterans had at least two INR results 
within the 12 month study period; 265 veterans had two or more INR results recorded in the 
six-month baseline period prior to their first HMR or index date, 279 veterans had two or 
more INR results recorded in the six-month period following their first HMR or index date 
and 229 veterans had two or more INR results in each six month period.  
Characteristics of the groups are shown in Table 2. The groups were well matched 
with respect to gender, prior hospitalisations, prior bleeding and thrombotic events and 
region. The median number of co-morbidities was statistically significantly higher in the 
HMR group. The median age was also one year older in the HMR group, which was of 
marginal statistical significance. 
In the overall study cohort, the median testing interval was approximately 16 days 
(range 1.0-65.7) and the mean TTR was 64.0 ± 27.3% (n=321). The proportion of veterans 
whose percentage TTR was > 60% and > 70% was 64.5% and 49.2%, respectively. The mean 
percentage TTR following HMR and index date was 63.0% ± 30.1% (n=98) and 67.0 ± 
27.7% (n=181), respectively (p=0.27). There was no significant change in the TTR in either 
of the groups or the overall veteran cohort in the period following the HMR or index date 
from the six-month baseline period (Table 3). 
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 Veterans living in outer regional and remote areas had significantly poorer INR 
control than those living in inner regional areas and major cities (mean TTR 49.9% ± 30.7% 
vs. 65.3% ± 30.7% for those living in outer regional/remote areas and those living in inner 
regional areas/major cities, respectively; p < 0.01).  
There was no change in the combined number of bleeding and thrombotic events 
leading to hospitalisation (4/281 (1.4%) in the HMR group versus 6/537 (1.1%) compared to 
the control group; p = 0.74). In the HMR group, there was no significant change in the 
combined number of bleeding and thrombotic events leading to hospitalisation before and 
after the HMR (1/281 (0.4%) versus 3/281 (1.1%), respectively; p = 0.62). 
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Discussion 
The mean percentage TTR for veterans included in the study was 64% and did not appear to 
be influenced by HMR. The degree of INR control in this study compares well with the mean 
TTR achieved in recent randomised trials comparing warfarin to the new anticoagulants 
dabigatran (64%), rivaroxaban (55%) and apixaban (62%)12-14 in a much older population, 
and exceeds the usual level of INR control achieved in the primary care setting in many 
countries.15  
A systematic review reported that INR control differed based on study site; in 
community-based studies, anticoagulation clinics and RCTs, mean TTR was 56.7%, 65.6% 
and 66.4%, respectively.15 In the literature, appropriate TTR benchmarks for patients taking 
warfarin are suggested to be 60-70%.16 In a study comparing the outcomes of patients 
randomised to dual antiplatelet therapy or warfarin, the benefits of warfarin were predicted to 
be lost using a population model when the TTR fell below 58%.2 If we accept the TTR 
benchmarks that have emerged internationally since our study, a TTR of 60% as a lower 
benchmark for acceptable INR control, around 35% of veterans in our study were below this 
figure. If upper benchmark of 70% is used, 51% of veterans were below this mark. 
There is a strong correlation between TTR and clinical outcomes for patients taking 
warfarin.3, 17-19 The generalisability of the results of trials comparing new anticoagulants to 
warfarin depends to a large extent on the TTR achieved in the trials, as it has been established 
that the efficacy, safety and cost-effectiveness of comparators to warfarin changes depending 
on the quality of INR control.20, 21 In the RE-LY trial, a 10% increase in TTR independently 
predicted a 20% lower rate (p < 0.001) of the composite clinical outcome (stroke, systemic 
embolism, or major haemorrhage).19 The number of clinical events in this study was too low 
to enable a statistical comparison of the clinical event rate and the degree of INR control. 
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Noting that the study was underpowered to detect differences in hospitalisation for 
major bleeding and thrombosis, we did not identify any effect of HMRs on hospital admission 
resulting from complications associated with warfarin therapy in veterans who had been 
taking warfarin for a period of at least six months. 
Two studies in Australia involving a combination of a series of medication review and 
point-of-care (POC) INR monitoring have found that this combination reduces the risk of 
complications with warfarin therapy in the early post-discharge period.22, 23 However, most of 
the beneficial effect of these interventions was due to a reduction in minor bleeding, and not 
events that resulted in hospitalisation. In the more recent study,23 the intervention was 
associated with significantly decreased rates of combined major and minor haemorrhagic 
events to day 90 compared to usual care. However, there were no significant differences in 
readmission and death rates, or in INR control between the groups. Furthermore, significant 
reductions in complications associated with warfarin therapy only occurred in the group of 
patients newly initiating, rather than continuing, warfarin therapy.  
It is therefore difficult to extrapolate the benefits of these interventions involving 
multiple home-visits to the effectiveness of a single HMR on people who are relatively stable 
on warfarin therapy (versus those recently discharged from hospital and/or recently initiated 
on warfarin). Additionally, the focus of the medication review in the studies was directly on 
warfarin, while this may often not be the reason for the initiation of an HMR in people who 
are stabilised on warfarin therapy. In a retrospective study by Roughead et al, using 
administrative claims data from the DVA, the effect of a single HMR on Australian veterans 
and war widows 65 years and older who were taking warfarin was investigated.6 The study 
identified a 79% reduction in the likelihood of hospitalisation for bleeding between two and 
six months following the HMR. This analysis did not include INR data, so it is unclear 
whether the HMR influenced INR control. The results of the present study, albeit in a smaller 
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subset of the veteran population, suggest that this reduction in hospitalisation occurred 
independently of improved INR control. However, it remains possible that if INR data were 
available to examine TTR in the larger cohort investigated in Roughead et al’s study, an 
improvement in both INR and warfarin-related hospitalisations may have been detected. 
In order to obtain INR histories for included patients in the present study, the 
investigators were required to obtain consent from veterans. This meant that it was not 
possible to obtain information from veterans who had died either during the study period or in 
the time following the study period prior to the DVA mail-out, and excluded veterans who 
were readmitted to hospital with a major bleeding or thrombotic event and subsequently died. 
Therefore, we were not able to investigate the data of the entire veteran cohort who were 
taking warfarin during the study period. It is possible that the more seriously ill veterans, and 
perhaps those most likely to suffer from adverse events related to warfarin were not included 
as a result of this methodology. This may have underestimated any influence that HMRs may 
have had on the clinical outcomes of warfarin therapy or on INR control. The low rate of 
major bleeding in this study (equivalent to 2% p.a.) might be explained by careful selection of 
veterans who are candidates for warfarin by prescribers, the relatively high standard of INR 
control, the exclusion of veterans who suffered major bleeding events and subsequently died 
(due to the nature study methodology) or a combination of these factors.  
 
Limitations  
There were several methodological limitations to the study, which have largely been 
previously discussed. It should be acknowledged that while the percentage TTR is strongly 
associated with bleeding and thromboembolism in people taking warfarin, the absence of a 
change in TTR as a result of an HMR in this study does not rule out the possibility that HMRs 
may improve these outcomes through alternative means. Additionally, the data available from 
Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
     12 
 
the DVA was limited in respect to the documentation of co-morbidities, which meant that it 
was impossible to determine the indication for warfarin from the data available. Therefore, a 
target INR of 2.0 to 3.0 was assumed for all veterans. It is likely that this would have resulted 
in an under-estimation of the TTR rather than an over-estimation of the degree of INR 
control. INR data were only available for approximately 40% of the included veterans. In 
some cases, the pathology provider did not comply with the joint request from the research 
team, the DVA and the veteran for the data to be released. In some cases the pathology 
provider only held a proportion of the INR data available; the veteran may have changed 
provider or office-based INR testing was used (in which case it was not available to the 
pathology provider). It was not possible to identify which veterans may have received office-
based point of care INR testing during the study period and it is therefore unknown whether 
their INR control is comparable to that of the veterans included in this study.  
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Conclusions 
The overall level of INR control in the veterans participating in the study was good, and 
comparable to that achieved in RCTs, which generally involve a younger, healthier cohort. 
However, there appear to be a relatively large group of patients who would benefit from 
interventions to improve their INR control. HMRs did not appear to influence the INR control 
of veterans whose pathology data was available for analysis. The previously reported effect of 
pharmacist-led medication review on reducing hospital admission is likely to be due to other 
factors. It is clear there is an ongoing need to regularly audit INR control in veterans taking 
warfarin and intervene as appropriate to maximise the benefits and minimise the risks of 
warfarin therapy. 
Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
     14 
 
Acknowledgements 
This research was supported by the Australian Government Department of Veterans’ Affairs. 
The Department of Veterans’ Affairs reviewed the content. The authors would like to 
acknowledge the support and assistance of staff who assisted with this project. In particular 
we would like to thank Mimi van Duren, Francene Benness and Will Hanham for their 
commitment and assistance throughout the project. We would also like to thank the veterans 
who consented to be involved in the project and also those who contacted us but were 
unfortunately not able to participate. We would also like to thank the pathology providers 







Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
     15 
 
References 
1. Oden A, Fahlen M. Oral anticoagulation and risk of death: A medical record linkage 
study. BMJ 2002; 325: 1073-5. 
2. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet 
therapy in atrial fibrillation depends on the quality of international normalized ratio 
control achieved by centers and countries as measured by time in therapeutic range. 
Circulation 2008; 118: 2029-37. 
3. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients 
randomized to warfarin therapy accprding to anticoagulant control. Arch Intern Med 
2007; 167: 239-45. 
4. Gilbert AL, Roughead EE, Beilby J, et al. Collaborative medication management 
services: Improving patient care. Med J Aust 2002; 177: 189-92. 
5. Krass I, Smith C. Impact of medication regimen reviews performed by community 
pharmacists for ambulatory patients through liaison with general medical practitioners. 
Int J Pharm Prac 2000; 8: 111-20. 
6. Roughead EE, Barratt JD, Ramsay E, et al. Collaborative home medicines review delays 
time to next hospitalization for warfarin associated bleeding in australian war veterans. J 
Clin Pharm Ther 2010; 36: 27-32. 
7. World Health Organisation Collaborating Centre for Drug Statistics Methodology. 
Anatomical therapeutic chemical code classification index with defined daily doses. 
2008. [cited 2nd July 2015]. Available from: http://www.whocc.no/atc_ddd_index/ 
8. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical 
Benefits [cited 2nd July 2015]. Available from: http:// www.pbs.gov.au  
Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
     16 
 
9. World Health Organisation. International statistical classification of diseases and related 
health problems: 10th Revision. 2002. [cited 2nd July 2015]. Available from: 
http://www.who.int/classifications/icd/en/ 
10. Australian Institute of Health and Welfare. Rural, regional and remote health. A guide to 
remoteness classifications. 2004. [cited 2nd July 2015]. Available from: 
http://www.aihw.gov.au/rural-health-remoteness-classifications/ 
11. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the 
optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9. 
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with 
atrial fibrillation. N Engl J Med 2009; 361: 1139-51. 
13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients 
with atrial fibrillation. N Engl J Med 2011; 365: 981-92. 
14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial 
fibrillation. N Engl J Med 2011; 365: 883-91. 
15. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation 
control: A systematic review and metaregression. Chest 2006; 129: 1155-66. 
16. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for 
the management of atrial fibrillation: An update of the 2010 ESC guidelines for the 
management of atrial fibrillation. European Heart Journal 2012; 33: 2719-47. 
17. Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in 
patients treated with vitamin k antagonists: Main determinant of quality of 
anticoagulation and predictor of clinical outcome. A retrospective study of 2300 
consecutive patients with venous thromboembolism. Br J Haematol 2005; 128: 513-9. 
Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
     17 
 
18. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse 
events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual 
Outcomes 2008; 1: 84-91. 
19. Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice 
is responsible for differences in the quality of anticoagulation control between centers 
and countries: An analysis of patients receiving warfarin in the randomized evaluation of 
long-term anticoagulation therapy (re-ly) trial. Circulation 2012; 126: 2309-16. 
20. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared 
with warfarin at different levels of international normalised ratio control for stroke 
prevention in atrial fibrillation: An analysis of the re-ly trial. Lancet 2010; 376: 975-83. 
21. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial 
fibrillation. Circulation 2011; 123: 2562-70. 
22. Jackson SL, Peterson GM, Vial JH, et al. Improving the outcomes of anticoagulation: An 
evaluation of home follow-up of warfarin initiation. J Intern Med 2004; 256: 137-44. 
23. Stafford L, Peterson GM, Bereznicki LR, et al. Clinical outcomes of a collaborative, 
home-based postdischarge warfarin management service. Ann Pharmacother 2011; 45: 
325-34. 
 
Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
     18 
 
 
Figure 1. Patient recruitment flow diagram 
Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
     19 
 
Table 1. ICD-10 primary diagnosis codes used to identify hospitalisation due to haemorrhagic 
and thromboembolic events 
 
ICD-10 code Description ICD-10 code Description 
Haemorrhagic events Thromboembolic events 
D683 Bleed due to 
anticoagulant 
G450,G451, G452, 
G453, G454, G458, 
G459 
Transient cerebral ischaemic 
attacks and related 
syndromes 
D698, D699 Haemorrhagic 
condition unspecified 
G460, G461, G462, 
G463, G464, G465, 
G466, G467, G468 
Vascular syndromes of brain 
in cerebrovascular diseases 
I60 I61 I62 Cerebral 
haemorrhage 
I260, I269 Pulmonary embolism 
K250, K252, 
K254,K259, K260, 
K262, K264, K266, 
K270, K272, K272, 
K276 
GI ulcer with 
haemorrhage 
I630, I631, I632, 
I633, I634, I635, 
I636, I638, I639 
Cerebral infarction 
K290 Acute haemorrhagic 
gastritis 
I64 Stroke, not specified as 
haemorrhage or infarction 
K280, K284, K286, 
K5701, K5703, K5711, 
K5713, K5721, K5723, 
K5731, K5733, K5743, 
K5751, K5783, K5791, 
K5793, K625, K661 
Other intestinal bleed I81 Portal vein thrombosis 
K920 Haematemesis I820, I821, I822, 
I823, I828,I829 
Other venous embolism and 
thrombosis 
K922 GI haemorrhage   
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unspecified 
H113, H313, H356, 
H431 
Eye bleeds   
M2501, M2502, M2503, 
M2504, M2505, M2506, 
M2509 
Haemarthrosis   
R040, R042, R048, 
R049 
Epistaxis   
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Table 2. Patient characteristics 
 
 HMR group 
n = 281 
Control group 
n = 537 
p-value 
Male gender (%) 181 (64.4) 349 (65.0) 0.87 
Median age (range) 84.0 (56.0-93.0) years  83.0 (41.0-94.0) years 0.047 
Median number of co-morbidities (range) 9.0 (1.0 - 28.0) 7.0 (1.0 - 30.0) 0.003 
Prior hospitalisations* 
  0 (%) 
  1 (%) 










Prior hospitalisation for a bleeding or 
thrombotic event (%)* 
3 (1.1) 8 (1.5) 0.76 
Prior hospitalisation for a bleeding event (%)* 1 (0.4) 2 (0.4) 0.99 
Prior hospitalisation for a thrombotic event 
(%)* 
2 (0.7) 6 (1.1) 0.72 
Region† 
  Major city (%) 
  Inner regional (%) 
  Outer Regional (%) 












Mean percentage TTR (SD) ‡ 64.8 (25.2) 68.3 (28.4) 0.32 
Median number of tests (range) ‡ 8.0 (2.0-30.0) 7.0 (2.0-52.0) 0.33 
Median testing interval in days (range) ‡ 12.6 (1.0-76.0) days 17.4 (1.0-70.5) days 0.002 
* In the six months prior to the HMR (HMR group) or index date (control group).  
† The region was unknown for four veterans. 
‡ Veterans with only one INR value recorded for the six months prior to the HMR or index date were excluded (n 
= 94 for the HMR group and n = 171 for the control group). 
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Table 3. Percentage TTR following HMR or index date* 
 
 Before After Mean difference p-value 
HMR group  
(n = 78) 
67.9 ± 23.3 69.6 ± 25.2 +1.7 0.63 
Control group  
(n = 151) 
70.4 ± 26.1 68.5 ± 26.1 - 1.9 0.40 
Overall  
(n = 229) 
69.6 ± 25.1 68.9 ± 25.8 + 0.7 0.72 
*Only veterans with more than one INR value available for both the six months before and the six months 

















Bereznicki, L. and van Tienen, E. and Stafford, A. 2015. Home medicines reviews in Australian war veterans taking warfarin 
do not influence international normalised ratio control. Internal Medicine Journal. 46 (3): pp. 288-294.
